Experimental animal models of encapsulating peritoneal sclerosis

Peritoneal Dialysis International

Volumn 25, Issue SUPPL. 4, 2005, Pages

  Hoff, Catherine M ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Animal model; Encapsulating peritoneal sclerosis; EPS; Peritoneal fibrosis

Indexed keywords

5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; ALPHA SMOOTH MUSCLE ACTIN; ANGIOGENESIS INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; BENAZEPRIL; BLEACHING AGENT; CANDESARTAN; CHEMICAL COMPOUND; CHLORHEXIDINE GLUCONATE; COLLAGEN; COLLAGEN TYPE 1; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUMAGILLOL CHLOROACETYLCARBAMATE; GELATINASE A; GELATINASE INHIBITOR; GLUCOCORTICOID; INTERCELLULAR ADHESION MOLECULE 1; OLMESARTAN; PERITONEAL DIALYSIS FLUID; PIRFENIDONE; QUINAPRIL; RENIN INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN ANTIBODY;

ABDOMEN; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE MARKER; DRUG POTENCY; ENCAPSULATION; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; FIBROBLAST; FIBROSIS; INCIDENCE; INFLAMMATORY INFILTRATE; LONG TERM EXPOSURE; MEMBRANE DAMAGE; MESOTHELIUM; MICROSCOPY; NONHUMAN; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PH MEASUREMENT; PREDICTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RODENT; SCLEROSING PERITONITIS; TREATMENT PLANNING; UREMIA;

EID: 27744443448     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080502504s08     Document Type: Article

References (39)

1. Nomoto Y, Kawaguchi Y, Sakai S, Hirano H, Kubo H, Ohira S. et al. Sclerosing encapsulating peritonitis (SEP) in patients on continuous ambulatory peritoneal dialysis - definition, diagnosis, and treatment recommendations, 1997 update (Japanese). J Jpn Soc Dial Ther 1998; 31: 303-11.
2. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20(Suppl 4):S43-55.
3. Rigby RJ, Hawley CM. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant 1998; 13:154-9.
4. Mactier RA. The spectrum of peritoneal fibrosing syndromes in peritoneal dialysis. Adv Perit Dial 2000; 16: 223-8.
5. Nakayama M, Yamamoto H, Ikeda M, Hasegawa T, Kato N, Takahashi H, et al. Risk factors and preventive measures for encapsulating peritoneal sclerosis - Jikei experience 2002. Adv Perit Dial 2002; 18:144-8.
6. Yamamoto R, Nakayama M, Hasegawa T, Miwako N, Yamamoto H, Yokoyami K, et al. High-transport membrane is a risk factor far encapsulating peritoneal sclerosis developing after long-term continuous ambulatory peritoneal dialysis treatment. Adv Perit Dial 2002; 18:131-4.
7. Kawanishi H. Surgical treatment for encapsulating peritoneal sclerosis. Adv Perit Dial 2002; 18:139-43.
8. Honda K, Nitta K, Horita S, Tsukada M, Itabashi M, Nihei H, et al. Histologic criteria for diagnosing encapsulating peritoneal sclerosis in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 2003; 19:169-75.
9. Junor BJ, Briggs D, Forwell MA, Dobbie JW, Henderson I. Sclerosing peritonitis - the contribution of chlorhexidine in alcohol. Perit Dial Bull 1985; 5:101-4.
10. Mackow RC, Winchester JF, Argy WP, Matthews PM, Shields PA, Bates S, et al. Sclerosing encapsulating peritonitis in rats: an experimental study with intraperitoneal antiseptics. Contrib Nephrol 1987; 57:213-18.
11. Mackow RC, Argy WP, Winchester JF, Rakowski TA, Fields PA, Rotellar C, et al. Sclerosing encapsulating peritonitis in rats induced by long-term intraperitoneal administration of antiseptics. J Lab Clin Med 1988; 112:363-71.
12. Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12:14-27.
13. Yamamoto H, Nakayama M, Yamamoto R, Otsuka Y, Takahashi H, Kato N, et al. Fifteen cases of encapsulating peritoneal sclerosis related peritoneal dialysis: a single-center experience in Japan. Adv Perit Dial 2002; 18:135-8.
14. Ishii Y, Sawada T, Shimizu A, Tojimbara T, Nakajima I, Fuchinoue S, et al. An experimental sclerosing encapsulating peritonitis model in mice. Nephrol Dial Transplant 2001; 16:1262-6.
15. Sawada I, Ishii Y, Tojimbara I, Nakajima I, Fuchinoue S, Teraoka S. The ACE inhibitor, quinapril, ameliorates peritoneal fibrosis in an encapsulating peritoneal sclerosis model in mice. Pharmacol Res 2002; 46:505-10.
16. Levine S, Saltzman A. Abdominal cocoon: an animal model for a complication of peritoneal dialysis. Perit Dial Int 1996; 16:613-16.
17. Nakamoto H, Imai H, Ishida Y, Yamanouchi Y, Inoue T, Okada H, et al. New animal models for encapsulating peritoneal sclerosis - role of acidic solution. Perit Dial Int 2001; 21(Suppl 3):S349-53.
18. Okada H, Inoue T, Kanno Y, Kobayashi T, Watanabe Y, Ban S, et al. Selective depletion of fibroblasts preserves morphology and the functional integrity of peritoneum in transgenic mice with peritoneal fibrosing syndrome. Kidney Int 2003; 64:1722-32.
19. Nishino T, Miyazaki M, Abe K, Furusu A, Mishima Y, Harada T, et al. Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats. Kidney Int 2003; 64:887-96.
20. Nakai A, Satoh M, Hirayoshi K, Nagata K. Involvement of the stress protein HSP47 in procollagen processing in the endoplasmic reticulum. J Cell Biol 1992; 117:903-14.
21. Shioshita K, Miyazaki M, Ozono Y, Abe K, Taura K, Harada T, et al. Expression of heatshock proteins 47 and 70 in the peritoneum of patients on continuous ambulatory peritoneal dialysis. Kidney Int 2000; 57:619-31.
22. Mishima Y, Miyazaki M, Abe K, Ozono Y, Shioshita K, Xia Z, et al. Enhanced expression of heat shock protein 47 in rat model of peritoneal fibrosis. Perit Dial Int 2003; 23:14-22.
23. Shin GT, Kim SJ, Ma KA, Kim HS, Kim D. ACE inhibitors attenuate expression of renal transforming growth factor-β1 in humans. Am J Kidney Dis 2000; 36:894-902.
24. Border WA, Noble NA. Interactions of transforming growth factor-β and angiotensin II in renal fibrosis. Hypertension 1998; 31(Part 2):181-8.
25. Abe K, Miyazaki M, Yoshio Y, Nishino T, Furusu A, Harada T, et al. Angiotensin II blockade ameliorates peritoneal fibrosis and angiogenesis in mouse experimental model of peritoneal fibrosis caused by chlorhexidine gluconate (Abstract). J Am Soc Nephrol 2002; 13:309A.
26. Imai H, Nakamoto H, Fukushima R, Isjida Y, Yamanouchi Y, Suzuki H. Role of adhesion molecules in the progression of peritoneal sclerosis. Adv Perit Dial 2003; 19:180-5.
27. Suga H, Teraoka S, Ota K, Komemushi S, Furutani S, Yamauchi S, et al. Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Exp Toxicol Pathol 1995; 47:287-91.
28. Yoshio Y, Miyazaki M, Abe K, Nishino T, Furusu A, Harada T, et al. A novel angiogenesis inhibitor, TNP-470, ameliorates the progression of peritoneal fibrosis in mouse chlorhexidine gluconate model (Abstract). J Am Soc Nephrol 2002; 13:389A.
29. Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 2004; 65:1927-36.
30. Imai H, Nakamoto H, Fukushima R, Yamanouchi Y, Ishida Y, Suzuki H. Glucocorticoid protects against the development of encapsulating peritoneal sclerosis on peritoneal dialysis. Adv Perit Dial 2002; 18:124-30.
31. Hirahara I, Umeyama K, Urakami K, Kusano E, Masunaga Y, Asano Y. Serial analysis of matrix metalloproteinase-2 in dialysate of rat sclerosing peritonitis models. Clin Exp Nephrol 2001; 5:103-8.
32. Ro Y, Hamada C, Inaba M, Hayashi K, Sho I, Fukui M, et al. Effects of matrix metalloproteinase inhibitor ONO-4817 on morphological changes in chlorhexidine gluconate-induced peritoneal sclerosis rats (Abstract). J Am Soc Nephnol 2003; 14:593A.
33. Hekking LHP, Aalders MC, Van Geldenop F, Zweers MM, Struijk DG, Havenith CEG, et al. Effect of peritoneal dialysis fluid measured in vivo in a rat-model of continuous peritoneal dialysis. Adv Perit Dial 1998; 14:14-18.
34. Zweers MM, Splint U, Krediet RT, Struijk DG. Ultrastructure of basement membranes of peritoneal capillaries in a chronic peritoneal infusion model in the rat. Nephrol Dial Transplant 2001; 16:651-4.
35. Margetts PJ, Kolb M, Yu L, Hoff CM, Gauldie J. A chronic inflammatory infusion model of peritoneal dialysis in rats. Perit Dial Int 2001; 21(Suppl 3):S368-72.
36. Lee EA, Oh JH, Lee HA, Kim SI, Park EW, Park KB, et al. Structural and functional alterations of the peritoneum after prolonged exposure to dialysis solutions: role of aminoguanidine. Perit Dial Int 2001; 21:245-53.
37. Hekking LHP, Zareie M, Driespnong BAJ, Faict D, Welten AGA, de Greeuw I, et al. Better preservation of peritoneal morphologic features and defense after long-term exposure to a bicarbonate/lactate-buffered solution. J Am Soc Nephrol 2001; 12:2775-86.
38. Hoff CM, Piscopo D, Svatek JM, Holmes CJ, Honda K, Margetts PJ. Pilot study to establish an experimental animal model of EPS: potential contributing factors (Abstract). Perit Dial Int 2004; 24(Suppl 2):S4.
39. Margetts PJ, Kolb M, Galt T, Hoff CM, Shockley TR, Gauldie J. Gene transfer of transforming growth factor-β to the rat peritoneum: effects on membrane function. J Am Soc Nephrol 2001; 12:2029-39.